Literature DB >> 21956985

Lack of association between clinical outcome of Clostridium difficile infections, strain type, and virulence-associated phenotypes.

Stéphanie Sirard1, Louis Valiquette, Louis-Charles Fortier.   

Abstract

Clostridium difficile strain NAP1/027 (North American pulsed-field gel electrophoresis [PFGE] type 1 and PCR ribotype 027 [R027]) has been associated with recent outbreaks in North America and Europe. It has been associated with more severe disease symptoms, higher mortality rates, and greater risk of relapse. This strain is thought to produce more toxins and sporulate to higher levels. However, recent studies suggest that this may not always be the case. The objective of our study was to assess, in a nonoutbreak situation, whether specific strains, such as NAP1/027, were associated with more severe disease symptoms, higher toxin production, and/or greater sporulation in vitro. We isolated and characterized C. difficile strains from 21 patients with mild to moderate, severe, or complicated symptoms of C. difficile infection (CDI). The isolates were characterized by different molecular typing methods, including PCR ribotyping, tandem repeat sequence typing (TRST), and sequencing of the tcdC gene. Fourteen isolates were of PCR ribotype 027 with deletions in tcdC, but no association with severity or clinical outcome was found. We show by immunodot blot detection of toxins with monoclonal antibodies that all R027 isolates produced more TcdA and TcdB than other strains. On the other hand, they consistently produced fewer spores than non-R027 isolates. Taken together, our data suggest that NAP1/027 isolates are not always associated with more severe disease, even though they may produce larger amounts of toxins. Our study also suggests that current assertions regarding the NAP1/027 may not apply to all isolates and that other factors may come into play.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21956985      PMCID: PMC3233013          DOI: 10.1128/JCM.05053-11

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  42 in total

1.  Regulation of toxin synthesis in Clostridium difficile by an alternative RNA polymerase sigma factor.

Authors:  N Mani; B Dupuy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

2.  Regulated transcription of Clostridium difficile toxin genes.

Authors:  B Dupuy; A L Sonenshein
Journal:  Mol Microbiol       Date:  1998-01       Impact factor: 3.501

3.  Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile.

Authors:  S Stubbs; M Rupnik; M Gibert; J Brazier; B Duerden; M Popoff
Journal:  FEMS Microbiol Lett       Date:  2000-05-15       Impact factor: 2.742

4.  Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile.

Authors:  T Hundsberger; V Braun; M Weidmann; P Leukel; M Sauerborn; C von Eichel-Streiber
Journal:  Eur J Biochem       Date:  1997-03-15

5.  Development of a new PCR-ribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing.

Authors:  P Bidet; F Barbut; V Lalande; B Burghoffer; J C Petit
Journal:  FEMS Microbiol Lett       Date:  1999-06-15       Impact factor: 2.742

6.  Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile.

Authors:  Ludovic Lemee; Anne Dhalluin; Sabrina Testelin; Marie-Andre Mattrat; Karine Maillard; Jean-François Lemeland; Jean-Louis Pons
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

7.  Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196.

Authors:  S Perelle; M Gibert; P Bourlioux; G Corthier; M R Popoff
Journal:  Infect Immun       Date:  1997-04       Impact factor: 3.441

8.  Lack of association of tcdC type and binary toxin status with disease severity and outcome in toxigenic Clostridium difficile.

Authors:  Simon D Goldenberg; Gary L French
Journal:  J Infect       Date:  2011-03-21       Impact factor: 6.072

9.  Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates.

Authors:  Patrizia Spigaglia; Paola Mastrantonio
Journal:  J Clin Microbiol       Date:  2002-09       Impact factor: 5.948

10.  Genotypic differentiation of twelve Clostridium species by polymorphism analysis of the triosephosphate isomerase (tpi) gene.

Authors:  Anne Dhalluin; Ludovic Lemée; Martine Pestel-Caron; Francine Mory; Georges Leluan; Jean-François Lemeland; Jean-Louis Pons
Journal:  Syst Appl Microbiol       Date:  2003-03       Impact factor: 4.022

View more
  41 in total

1.  Microbial and metabolic impacts of trehalose and trehalose analogues.

Authors:  Yiming Zhang; Brian J DeBosch
Journal:  Gut Microbes       Date:  2020-04-24

2.  Detection of toxigenic Clostridium difficile: comparison of the cell culture neutralization, Xpert C. difficile, Xpert C. difficile/Epi, and Illumigene C. difficile assays.

Authors:  P Pancholi; C Kelly; M Raczkowski; J M Balada-Llasat
Journal:  J Clin Microbiol       Date:  2012-01-25       Impact factor: 5.948

3.  Clostridium difficile infection in older adults.

Authors:  Robin Lp Jump
Journal:  Aging health       Date:  2013-08-01

4.  Multilocus Variable-Number Tandem-Repeat Analysis of Clostridioides difficile Clusters in Ribotype 027 Isolates and Lack of Association with Clinical Outcomes.

Authors:  Julian R Garneau; Claire Nour Abou Chakra; Louis-Charles Fortier; Annie-Claude Labbé; Andrew E Simor; Wayne Gold; Matthew Muller; Allison McGeer; Jeff Powis; Kevin Katz; Jacques Pépin; Louis Valiquette
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

5.  The evolving epidemiology of Clostridium difficile infection in Canadian hospitals during a postepidemic period (2009-2015).

Authors:  Kevin C Katz; George R Golding; Kelly Baekyung Choi; Linda Pelude; Kanchana R Amaratunga; Monica Taljaard; Stephanie Alexandre; Jun Chen Collet; Ian Davis; Tim Du; Gerald A Evans; Charles Frenette; Denise Gravel; Susy Hota; Pamela Kibsey; Joanne M Langley; Bonita E Lee; Camille Lemieux; Yves Longtin; Dominik Mertz; Lorraine Maze Dit Mieusement; Jessica Minion; Dorothy L Moore; Michael R Mulvey; Susan Richardson; Michelle Science; Andrew E Simor; Paula Stagg; Kathryn N Suh; Geoffrey Taylor; Alice Wong; Nisha Thampi
Journal:  CMAJ       Date:  2018-06-25       Impact factor: 8.262

6.  NAP1 strain type predicts outcomes from Clostridium difficile infection.

Authors:  Isaac See; Yi Mu; Jessica Cohen; Zintars G Beldavs; Lisa G Winston; Ghinwa Dumyati; Stacy Holzbauer; John Dunn; Monica M Farley; Carol Lyons; Helen Johnston; Erin Phipps; Rebecca Perlmutter; Lydia Anderson; Dale N Gerding; Fernanda C Lessa
Journal:  Clin Infect Dis       Date:  2014-03-05       Impact factor: 9.079

7.  Clostridioides difficile Whole-genome Sequencing Differentiates Relapse With the Same Strain From Reinfection With a New Strain.

Authors:  Janice Cho; Scott Cunningham; Meng Pu; Ryan J Lennon; Jennifer Dens Higano; Patricio Jeraldo; Priya Sampathkumar; Samantha Shannon; Purna C Kashyap; Robin Patel
Journal:  Clin Infect Dis       Date:  2021-03-01       Impact factor: 9.079

8.  Markers of intestinal inflammation, not bacterial burden, correlate with clinical outcomes in Clostridium difficile infection.

Authors:  Rana E El Feghaly; Jennifer L Stauber; Elena Deych; Carlos Gonzalez; Phillip I Tarr; David B Haslam
Journal:  Clin Infect Dis       Date:  2013-03-13       Impact factor: 9.079

Review 9.  Variations in virulence and molecular biology among emerging strains of Clostridium difficile.

Authors:  Jonathan J Hunt; Jimmy D Ballard
Journal:  Microbiol Mol Biol Rev       Date:  2013-12       Impact factor: 11.056

10.  Factors Associated With Complications of Clostridium difficile Infection in a Multicenter Prospective Cohort.

Authors:  Claire Nour Abou Chakra; Allison McGeer; Annie-Claude Labbé; Andrew E Simor; Wayne L Gold; Matthew P Muller; Jeff Powis; Kevin Katz; Julian R Garneau; Louis-Charles Fortier; Jacques Pépin; Suzanne M Cadarette; Louis Valiquette
Journal:  Clin Infect Dis       Date:  2015-09-03       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.